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Inhibition of diabetic nephropathy by a GH antagonist: A molecular
analysis. Streptozotocin-treated C57B1/SJL mice developed glomerular
hypertrophy and light microscopic lesions mimicking human diabetic
glomeruloscierosis. In contrast, there were no glomerular hypertrophy and
lesions in diabetic mice transgenic (TG) for a mutated growth hormone
(bGH-G119K) that competes with native endogenous GH and results in
dwarfism. We examined the molecular events underlying these findings.
The non-transgenic (non-TG) diabetic mouse glomeruli had an increase in
mRNA coding for a1IV collagen, laminin Bi, TGF-j31, 72 kDa collage-
nase, and TIMP-3. In contrast, glomerular type IV collagen and laminin
Bi mRNA levels were normal in diabetic TG dwarf mice. However, the 72
kDa gelatinase, TIMP-3, and TGF-131 mRNAs were elevated in the
diabetic dwarfs. Type IV collagen and laminin accumulated in the
glomeruli of diabetic non-TG, but not of diabetic dwarf mice, by immu-
nofluorescence microscopy, confirming the mRNA data. GH binding
protein mRNA levels were comparable in glomeruli from dwarf and
non-TG mice, both diabetic and non-diabetic. We did not detect GH
receptor mRNA in glomeruli. These data suggest that diabetic glomeru-
loscierosis is associated with an increase in type IV collagen and laminin
synthesis, and that these changes do not occur in mice transgenic for
bGH119K, a functional antagonist of GH. The increase of 72 kDa
gelatinase, TIMP-3, and TGF-/31 mRNAs, independent of GH, suggested
that these changes induced by hyperglycemia were not sufficient for the
induction of glomerulosclerosis.
Growth hormone (GH) plays a role in the development of
glomerulosclerosis [1—3]. Mice transgenic for native bovine
growth hormone (bGH) express elevated levels of bGH, have a
giant phenotype, and developed diffuse progressive glomerulo-
sclerosis leading to end-stage renal failure and death within 8 to 9
months of age [1]. In contrast, glomeruli were normal in mice
transgenic (TG) for a mutated form of bGH (bGH-G119K),
which acted as an antagonist of endogenous GH and resulted in
dwarfism [2—5]. Since a large body of literature suggested that GH
is permissive for the development of glomerulosclerosis and of
other diabetic complications [6, 7], we induced diabetes in dwarf
and normal littermate mice using streptozotocin (STZ) to test the
hypothesis that TG mice would not develop diabetic nephropathy.
While the levels of glycemia were comparable in both groups of
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mice, proteinuria and morphologic lesions characteristic of dia-
betic nephropathy were present in non-TG littermates but not in
dwarf mice [8]. We now report on the molecular changes which
underlie the glomerular extracellular matrix (ECM) findings. We
found that there was no accumulation of type IV collagen and
laminin in glomeruli of dwarf mice, and that the al(IV) collagen
and laminin Bi gene expression was normal in microdissected
glomeruli by competitive PCR. However, 72 kDa collagenase,
TIMP-3 and TGF-/31 mRNA levels were elevated in both STZ
treated dwarf and non-TG mice. Diabetic dwarf mice had reduced
liver GH receptor binding sites [8], but we did not find GH
receptor (GHR) gene expression in the glomeruli of diabetic or
non-diabetic dwarf and non-TG mice. In contrast, GHBP mRNA
was present at comparable levels in the glomeruli of both dwarf
and non-TG mice, irrespective of the presence or absence of
diabetes. In summary, these data provide further evidence that the
development of diabetic nephropathy requires a functional
growth hormone.
Methods
Animals
The bGH-G119K transgenic mice were described in detail
previously [2, 4, 5]. They had a dwarf phenotype due to the
expression of a mutated GH which acts as an antagonist of native
GH [91. STZ treated [8] dwarf mice (N = 4) and their non-TG
littermates (N = 4) were compared with corresponding vehicle
treated dwarf (N = 4) and non-TG Iittermate (N = 4) mice. Since
previous data from our laboratory indicated that there was little
variation in mRNA levels between individual animals, we used a
limited number of animals in this study [10—13]. Animals were
sacrificed 12 weeks after the onset of diabetes and the glomeruli
were microdissected as described [11].
STZ treatment
Diabetes was induced in four week old female dwarf mice and
their non-TG littermates using STZ [14]. Four to eight intraper-
itoneal daily injections of 80 .tg/g body wt of STZ, or 80 .dIgbody
wt of vehicle solution (citrate buffer) were administered. Mice
were fed Purina Rodent Chow 5004 (Ralston Purina, St. Louis,
MO, USA) ad libitum. Experimental and control animals were
weighed, bled, and blood glucose levels were determined daily
during STZ treatment and each week thereafter [8, 15]. The mice
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Table 1. Dwarf and non-TG mice after diabetes induction
Group
Body weight
g
Kidney weight
mg
Kidney/body wt
ratio
Blood glucose
mg/dl
Plasma IGF-1
ng/ml
Diabetic TG 8.7 2.0k' 99.3 13.3 0.013 0002d 300—500 43.0 55b
TG 15.6 2.0 93.0 5.7 0.006 0.001 89—135 110.5 26
Diabetic, non-TG 15.6 3.8a 201.1 248bc 0.015 0.002e 300—500 267.6 74
Non-TG 23.4 0.9 156.0 7.0l 0.007 0.00 89—135 372.3 67
a Significantly different from non-diabetic littermates, P < 0.03
b Significantly different from non-diabetic transgenic, P < 0.001
C Significantly different from non-transgenic non-diabetic, P < 0.0005d Significantly different from TG (P < 0.001), not different from diabetic, non-TG (P> 0.05)
C Significantly different from non-TG (P < 0.001)
were followed for 12 weeks, without insulin treatment. At sacri-
fice, mice were weighed and the kidney weights recorded. Plasma
levels of IgF-1 were measured using IgF-1 RIA kits (Nichols
Institute, San Juan Capistrano, CA, USA) [81.
Kidney histology and morphometty
Coronal kidney sections were fixed in Carnoy's fixative and
embedded in glycol methacrylate. Four micrometer sections were
stained with periodic acid-Schiff (PAS) and examined by light
microscopy [2].
The profile areas of all the glomeruli present on a section
(between 60 and 100) were measured with a computer-assisted
planimeter for morphometric analysis, as described previously [2,
8]. Mean glomerular volume was derived from the harmonic mean
of the glomerular equatorial surface area [2].
The degree of mesangial sclerosis was quantitated on a scale
from 0 to 4 using a semiquantitative scoring method previously
published [16, 17].
Immunohistochemistiy
Paraffin embedded kidney sections were deparaffinized and
coated with fluorescein isothiocyanate-conjugated rabbit anti
mouse type IV collagen (Biodesign, Kennebunkport, ME, USA)
or rabbit anti-rat laminin (Chemicon International Inc., Te-
mecula, CA, USA) followed by biotin conjugated goat anti-rabbit
fluorescein isothiocyanate (Zymed Laboratories, Inc., San Fran-
cisco, CA, USA) [2]. The sections were scored for fluorescence
intensity, from 1 to 4+, by an observer who was blinded to the
experimental group [2]. Staining for TGF-f31 and TGFI3-receptor
was performed on formalin fixed—paraffin embedded tissue, fol-
lowing digestion with hyaluronidase as published, using an avidin-
biotin peroxidase kit (Zymed) [18].
Glomerular microdissection and reverse transcription
After anesthesia with sodium pentobarbital (50 j.tg/g body wt,
i.p.), mice were sacrificed by decapitation. Left kidneys were
perfused with saline containing collagenase and RNase inhibitors.
Glomeruli were isolated by microdissection, permeabilized, soni-
cated, and eDNA was obtained after reverse transcription in situ
as described previously 10—13]. The right kidney was used for
histologic examination.
Primer construction and competitive PCR
Primers. The mouse a (IV) collagen, ts (I) collagen, laminin
B1, 72 kDa collagenase, TGF-/31 and J3-actin primers were
described previously [10-43]. The mouse TIPM-3 primer pair was
sense 5'-AGC CTC TGA AAG TCT TFG TG-3' and antisense
5'-TGG GAA GAG TIA GTG TCT GG-3', to yield an expected
PCR product of 448 bp. Cloning studies in mice showed that
GHBP is the product of an alternative splicing event during
processing of the full-length GHR mRNA. GHR has the same
extracellular domain (exon 2 to 7) as GHBP, except that it lacks
exon 8, and has a unique exon, exon 8A [19]. Thus, the mouse
GHR primer pair was sense 5'-CGC CCT GAT TAT GTC TCT
GCT GGA AAA-3' (exon 5) and antisense 5'-TAA GAA CCA
TGG AAA CTG GAT-3' (exon 8), to yield an expected PCR
product of 511 bp. The mouse GHBP primer pair was sense
5'-CGC CCT GAT TAT GTC TCT GCT GGA AAA-3' (exon 5)
and antisense 5'-GGT GCC CAC AAG GCT AGG GAT-3'
(exon 8A), to yield an expected PCR product of 581 bp.
The primers were selected such that only specific mRNA-
derived cDNA sequences, but not genomic DNA sequences would
be amplified. Restriction enzyme analysis was performed on each
of the PCR products to confirm the amplification of specific
mRNA sequences (as previously described) [101.
Standard PCR. Standard PCR was performed for GHR, GHBP,
and al type I collagen.
Competitive PCR. The mutated eDNA templates competed with
the test eDNA on an equimolar basis, as previously described
[10—131. For TIMP-3, a deletion eDNA mutant template was
developed to create a 48-bp deletion in the middle of the
molecule, resulting in a mutant cDNA of 400 bp.
To quantify eDNA, competitive PCR assays were performed by
the addition of decreasing amounts of mutant templates to
glomerular eDNA. The amount of glomerular cDNA was derived
from linear regression analysis, with duplicate or triplicate assays
[10—13]. The mean values for diabetic mice are expressed as a
percentage of those for the corresponding non-diabetic mice.
Statistical methods
All values were expressed as mean SD. Comparisons between
groups were made by Mann-Whitney or Student's t-test and by
one-way analysis of variance using Tukey-Kremer as a post test.
P < 0.05 was considered statistically significant. The eDNA levels
were compared between groups by using the unpaired t-test.
Results
Kidney weight
The mean kidney weight and the kidney/body wt ratio increased
in both dwarf and non-TG mice after the induction of diabetes
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Fig. 1. Glomeruli of diabetic [DM(+)j and
nondiabetic [DM(—)] mice. A. Dwarf DM (—).
B. Dwarf DM (+). C. Non-TG DM (—); D.
Non-TG DM (+) (periodic acid-Schiff stain,
original magnification, X400).
(Table 1). The diabetic mice in both groups were growth retarded,
but this was accentuated in the dwarf mice.
Plasma IGF-1 levels
As previously published, the dwarf mice have very low plasma
IGF-1 levels [5, 81. The serum plasma levels were further de-
creased in diabetic dwarf mice (Table 1). There was a trend
toward lower plasma IGF-1 levels in non-TG diabetic mice, but
this did not reach statistical significance.
Kidney histology and glomerular volume
Diabetic non-TG mice exhibited diffuse, but moderate, glomer-
uloscierosis with a diffuse increase in PAS positive material,
consistent with the previous series of experiments [8]. The number
of cells in the mesangial areas did not appear to be increased in
the diabetic mice. The lesions were somewhat irregular from one
glomerulus to the next, but there were no normal glomerular tufts
in the diabetic non-transgenic mice. The glomerular vascular
spaces appeared dilated, but there was no apparent thickening of
the peripheral glomerular basement membrane walls. In the
diabetic non-TG mice, the mesangial sclerosis appeared distrib-
uted equally between the cortical and juxtamedullary regions.
There was occasional thickening of Bowman's capsules. Many
tubules contained PAS positive droplets in the epithelial cells. In
contrast, there were no glomerular and tubular lesions in the STZ
treated dwarf mice and there was no evidence of an increase in
mesangial matrix (Fig. 1). The mean score for mesangial sclerosis
was 1.6 0.2 for the STZ non-TG versus 0.2 0.1 for the STZ
dwarf mice. The glomerular volumes of diabetic non-TG mice
were significantly increased, compared to their controls (STZ
treated vs. vehicle: 3.19 0.15 vs. 2.06 0.13 X i0 j.m3, P <
0.001). Glomerular volume did not change in diabetic dwarf mice
(STZ treated vs. vehicle, 1.39 0.05 vs. 1.35 0.09 x IO j.tm3,
P = 0.30), consistent with our previous observations [8, 151.
Immunochemical staining
The staining intensity for type IV collagen was accentuated in
the expanded mesangium of non-TG diabetic mice, but not in the
glomeruli of dwarf diabetic mice (Fig. 2). Similarly increased
laminin staining was found in the mesangium and peripheral
basement membranes in the non-transgenic diabetic mouse gb-
meruli. The pattern and intensity of laminin staining were similar
in the diabetic and non-diabetic dwarf mice (Fig. 3). There was no
detectable TGF-/3 in the gbomeruli of any of the mice, whereas it
was expressed in comparable intensity in the collecting tubules of
all groups. Small amounts of TGF-/3 receptor staining were found
in the mesangial areas in all mice tested, but there were no
differences between the different groups of mice.
Quantitation of glomerular mRNA
The absolute values, showed in Table 2, were normalized to
j3-actin before calculating the % changes (Figs. 4 and 5). The
mean glomerular cs1(IV) mRNA level was increased 1.9-fold in
STZ treated non TG mice (192.6 14.3 vs. 100.0 4.96%, P <
0.0001), but there was no significant difference between STZ
treated and untreated dwarf mice (107.5 9.14 vs. 100.0
12.8%). Laminin B1 mRNA levels were increased 1.5-fold in STZ
treated non-TG (146.1 18.4 vs. 100.0 5.9%, P < 0.005). There
was no significant difference in gbomerular laminin B1 mRNA
levels between diabetic and non-diabetic dwarf mice (100.12
11.98 vs. 100.0 16.60%). Gbomerular 72 kDa collagenase
mRNA levels were increased 2.1 fold in diabetic non-TG mice
(215.45 44.8 vs. 100.0 32.12%, P < 0.005) and 1.7-fold in
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Fig. 2. Immunofluorescence microscopic
localization of type IV collagen in glomendi. A.
Dwarf DM (—). B. Dwarf DM (+). C. Non-TG
DM (—). D. Non-transgenic DM (+). (Original
magnification, x400).
Fig. 3. Immunofluorescence microscopic
localization of laminin in glomendi. A. Dwarf
DM (-). B. Dwarf DM (+). C. Non-TG DM
(—). IL Non-TG DM (+) (Original
magnification, X400).
STZ-treated dwarf mice (175.27 33.05 vs. 100.0 26.1%, P < 22.4 vs. 100.0 8.59%, P < 0.01), and 1.4-fold in diabetic dwarf
0.01). Glomerular TIMP-3 mRNA level was increased 1.7-fold in mice (139.65 16.6 vs. 100.0 17.5%, P < 0.002). Alpha-i type
STZ treated non-TG mice (172.27 29.36 vs. 100.0 8.24%, P < I collagen was not detected by PCR, even when the number of
0.005) and 1.75-fold in diabetic dwarf mice (175.14 46.4 vs. cycles was increased to 42. There were no significant differences in
100.0 17.85%, P < 0.05). Glomerular TGF-131 mRNA levels the glomerular f3-actin mRNA levels between diabetic and non-
were increased 1.5-fold in STZ treated non-TG mice (147.05 diabetic mice in either non-TG or dwarf mice (non-TG, 109.74 ±
WT 360 bp
Mutant 282 bp
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Table 2. Glomerular mRNA quantitation by competitive PCR
N al (IV) Laminin 72 kDa TIMP-3 TGF-13 p-actin
Non-TG (DM—) 4 211.4 23.3 98 5.2 18.6 1.5 101.2 7.5 56.7 2.8 281.2 20.4
Non-TG (DM+) 4 445.0 21.4 156.3 19.3 39.0 9.6 192.3 26.3 92.6 14.5 308.5 3.1
TG (DM—) 4 127.8 18.3 71.2 10.2 12.3 3.2 75.0 13.4 31.5 5.2 180.9 5.1
TG (DM+) 4 146.5 10.3 77.5 11.6 23.3 4.8 148.0 26.6 46.7 4.3 195.1 11.2
Fig. 4. TGF-pI cDNA, quantitation by competitive PCR. An
aliquot (equivalent to 1/10th of a glomerulus) of eDNA from
a pool of reverse-transcribed glomeruf i was coamptified with
TGF-/31 primers and with TGF-j31 mutant eDNA template.
After electrophoresis, the experimental (WT)(360 bp) and
mutant (282 bp) PCR products were separated. A. The
amount of mutant template per tube was 0.002, 0.0015, 0.001,
and 0.0005 attomoles (lanes 1 to 6, respectively). B. The
experimental (WT) and mutant bands were quantitated by
scanning the negative image by laser densitometry. The ratio
of the mutant to experimental (WT) band density was plotted
as a function of the initial mutant template for each PCR,
and a linear regression curve was drawn. The amount of
experimental eDNA was calculated to be the X axis value at
which the mutant/experimental ratio was 1.0 (r = 0.99, for
this assay).
4.66 vs. 100.0 7.25%; dwarf mice, 107.89 5.71 vs. 100.0
2.84%).
Glomendar GHR and GHBP mRiVA
Using the mouse liver cDNA as a positive control, we were
unable to detect GHR mRNA in glomeruli isolated from both
control and diabetic dwarf and non-TG mice. However, GHBP
mRNA was present in glomeruli of both dwarf and non-TG mice.
Interestingly, there were no differences in the expression of
GHBP between diabetic and non-diabetic mice by laser densitom-
etry scanning (diabetic 0.44 0.06 vs. non-diabetic dwarf mice
0.47 0.07; non-TG diabetic 0.49 0.08 vs. non-TG non-diabetic
mice 0.49 0.08; Fig. 6).
Discussion
Growth hormone has been postulated to play a role in the
metabolic derangement of diabetes mellitus and in the complica-
tions of the disease [6, 20—251. Therefore, we had examined the
hypothesis that the inhibition of growth hormone action might
provide the means to prevent glomerular complications [8, 15].
Flyvberg and Muchaneta-Kubara examined dwarf rats which have
a GH deficiency due to a spontaneous mutation [24, 25]. They
rendered the rats diabetic with STZ and followed them for seven
days, at which time they noted that the dwarfs were largely
protected from diabetic kidney and glomerular hypertrophy. Both
groups postulated that these early effects were growth hormone
dependent and were mediated by increased kidney levels of
IGF-1. Our data confirms these findings, in that the kidney weight
and kidney/body wt ratios were increased in both dwarf and
littermate control mice after the induction of diabetes. Further-
more, we found that the hypertrophy persists to at least 12 weeks
after diabetes induction.
Recently we have shown that glomerular hypertrophy and
glomerulosclerosis are not tightly linked [26], and that mesangial
cell turnover and collagen synthesis are separable in vitro [27]. We
had previously shown that mice transgenic for IGF-1 had kidney
and glomerular hypertrophy, but they did not develop glomeru-
Iosclerosis [1]. Taken together, these observations provide evi-
dence that IGF-1 plays a role in glomerular (and kidney) hyper-
trophy, but that it is not directly linked to the development of
glomerulosclerosis. However, we have shown that mice transgenic
for growth hormone develop severe glomerulosclerosis which
results in death in uremia [1]. Thus, the expression of growth
hormone in excess amounts appears to play a direct role in the
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Fig. 5. Glomerular mRNA levels. Increased glomerular a (IV) collagen and Laminin B1 mRNA in non-TG diabetic mice, but not in dwarf diabetic mice.
Increased glomerular 72-kd collagenase, TIMP-3 and TGF-131 mRNA in both non-TG diabetic and diabetic dwarf mice. A. a (IV) collagen. B. Laminin
B1. C. TIMP-3. D. 72 kDa collagenase; E. TGF-pl; F. f3-actin.
induction of glomeruloscierosis. The development of mice trans-
genie for a mutated form of GH, which acts as a GH antagonist,
provided the opportunity to determine whether long-term GH
inhibition prevented the development of diabetic glomeruloscie-
rosis [8, 15]. Diabetic dwarf and non-TG mice had similarly
elevated blood glucose levels and plasma JOE-i levels were
decreased in diabetic dwarf mice, but not in diabetic non-TG
mice. The histologic features of diabetic glomeruloscierosis devel-
oped in the non-TO mice, but not in dwarf mice. Thus, the
overexpression of a GH antagonist, which suppressed endogenous
GH, prevented the development of glomeruloscierosis in mice
with uncontrolled hyperglycemia. However, the mechanism(s) of
prevention of the histologic lesions in glomeruli remained unclear.
The current study was undertaken to assess the molecular changes
underlying the histologic observations. We focused on compo-
nents of extracellular matrix synthesis and degradation, since the
amount of deposited glomerular ECM represents the balance
between these two processes [28].
Studies of glomeruli isolated from STZ-diabetic rats revealed a
significant increase in al(IV) collagen, laminin Bi and B2 mRNA
levels [291. Insulin treatment resulted in decreased glomerular
ECM gene expression [29]. These data suggested that the diabetic
milieu stimulated the glomerular synthesis of a(IV) collagen and
laminin. The possibility that a decreased degradation of matrix
proteins might explain the accumulation of ECM has also been
entertained [28, 30—33]. It has been reported that mRNA levels
for metalloproteinase MMP-1 and MMP-3 were decreased in
STZ-diabetic rats, whereas those for TIMP-1 were significantly
increased [32]. Thus, abnormalities in the regulation of MMPs
and TIMP-1 genes may contribute to the progression of glomer-
ular lesions in diabetic rats. We found that the levels of mRNA
encoding al(IV) collagen and laminin Bi were significantly
increased in the non-TG mice after a diabetes duration of 12
weeks, but not in the diabetic TG dwarf mice. These data were
consistent with the results of the immunofluorescence staining
patterns of type IV collagen and laminin. We did not detect
mRNA coding for type I collagen, a component which is ex-
pressed in human diabetic glomeruli, but which is largely re-
stricted to late lesions [34]. The absence of type I collagen in the
affected glomeruli may be due either to a species difference or the
fact that we examined relatively early lesions.
Rather than a decrease in 72 kDa collagenase, which was
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Fig. 6. Glomerular GHBP mRNA. The size of
the amplified product was 581 bp. A. TG mice;
lanes 1 to 4 diabetic, lanes 5 to 8 non-diabetic
mice. B. Non-transgenic mice; lanes 1 to 4
diabetic, lanes 5 to 8 non-diabetic mice.
reported in rats [32, 331,we found increased 72 kDa collagenase
mRNA levels in both the non-TG and dwarf diabetic mice. This
discrepancy may be the result of species differences, the duration
of diabetes, or the experimental techniques. For instance, in the
present study we examined microdissected glomeruli, whereas
others utilized total cortex or glomeruli isolated by sieving. We
previously showed that TIMP-1 gene is not expressed in mouse
glomeruli [351. TIMP-3, a novel member of the TIMP family was
found to be expressed in the kidney [36]. In this study we found
that TIMP-3 mRNA was present in glomeruli and that the mRNA
levels were elevated in both diabetic non-TG and dwarf mice.
TGF-p stimulates the synthesis of matrix components and
simultaneously blocks matrix degradation by decreasing the syn-
thesis of matrix metalloproteinases and increasing the levels of
tissue inhibitors of metalloproteinases (TIMPs) [37—39]. It has
also been associated with renal hypertrophy in diabetic rats and
mice [40]. We found that the levels of TGF-/31 mRNA were
elevated in the enlarged and sclerotic glomeruli of diabetic
non-TG mice. However, it was also elevated in diabetic dwarf
mice, which had neither large glomeruli nor glomeruloscierosis.
The current data suggested that the role of TGF-pl in diabetic
glomerular hypertrophy and matrix expansion may need to be
reevaluated [41]. The data are, however, consistent with in vitro
data which showed that TGF-/31 levels were directly related to
hyperglycemia [40]. Since we did not find TGF-J31 protein by
immunoperoxidase staining in diabetic non-TG or dwarf mice, we
cannot exclude the possibilities that the increased glomerular
TGF-pl mRNA levels were untranslated or that the peptide was
present in minute amounts that could not be detected by histo-
chemical methods.
The current study suggested that hyperglycemia or insulin
deficiency may have had direct effects on the regulation of
TGF-131, 72 kDa collagenase and TIMP-3 gene expression. It was
unclear what mediated the increased type IV collagen and laminin
gene expression, but it appeared to require functional GH.
We also examined glomeruli for the presence of growth hor-
mone binding protein (GHBP) and growth hormone receptor
(GHR) mRNAs to determine whether GH could directly affect
the glomerulus. GHBP mRNA was found in the glomeruli of both
diabetic and non-diabetic dwarf and non-TG mice, and it was
present at essentially identical levels. GHR mRNA was not found
in the glomeruli of any of the mice, while it was readily identified
in liver. Although GHR and GHBP have been found to be both
widely coexpressed, their expression has not always been found to
be coordinately regulated and there may be tissue-specific alter-
native splicing [42—44]. We did not find a difference in GHBP
gene expression between diabetic and non-diabetic mouse gb-
meruli, but it has been reported that GHR and GHBP mRNA
were significantly increased in total kidney of STZ treated rats
[45]. Our results confirm previous data suggesting that GHR
expression may be restricted to the tubules [46]. We found that
GHBP mRNA was expressed in mouse glomeruli, and that the
levels were not affected by the presence of diabetes or functional
GH. Thus, while these data raise the possibility that GH may
directly affect glomerular function, further studies are required.
In summary, we found that the absence of glomerulosclerosis
most likely was due to interruption of a GH-mediated increase in
glomerular type IV collagen and laminin Bi synthesis and accu-
mulation. This GH effect was selective, since TGF-/31, 72 kDa
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collagenase and TIMP-3 gene expression was elevated in diabetic
dwarf mice. The dwarf transgenic mouse may be a useful model in
elucidating the cellular and molecular mechanisms involved in
diabetic nephropathy.
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